Natco Pharma fell 4.71% to Rs 1110 after the Delhi High Court allowed interim injunction application against company that was filed by FMC Corporation on CTPR (Chlorantraniliprole).
The generic drug maker was engaged in a legal battle with California-based agriculture sciences company FMC over the use of an insecticide CTPR that is used in several crops.
Natco Pharma had filed a suit for declaration of freedom to use of CTPR, at the City Civil Court, Hyderabad, in the month of September 2019. FMC had counter-sued before the Delhi High Court, in November 2019, claiming patent infringement.
In February this year, Natco had received approval of registration by the Central Insecticide Board & Registration Committee (CIB&RC) for indigenous manufacture of CTPR Technical.
CTPR is also Natco's first key technical product to be rolled out from Crop Health Sciences (CHS) division.
CTPR technical is formulated into broad-spectrum insecticides used in several crops for better pest management. The active ingredient is used across products commercialised by FMC under its brands Coragen and Ferterra.
The Hyderabad-based company added that it was hoping to bring formulations based on the product with affordability and accessibility to farmer across the country.
The sales generated from CTPR containing products in India, inclusive of third-party marketing companies, as per declaration given by FMC was estimated to be Rs 1540 crore in 2016.
The Hyderabad-based company believes the current market size to be over Rs 2000 crore.
Natco Pharma manufactures a comprehensive range of branded and generic dosage forms, bulk actives and intermediates for both Indian as well as International markets.
The drug maker posted a 43% decline in consolidated net profit to Rs 53 crore on a 27.15% fall in revenue from operations to Rs 331.3 crore in Q4 FY21 over Q4 FY20.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU